“…55 Jejunal involvement has been recognized as an independent marker of severity in CD, being associated with an increased risk of relapse, 55 higher use of corticosteroids (HR 1.24; 95% CI: 1.02 -1.50) and thiopurines (HR 1.26; 95% CI: 1.06 -1.49), higher rates of strictureplasties (RR 2.52; 95% CI: 1.60 -3.96), hospitalizations (RR 1.29; 95% CI: 1.14 -1.47), and longer hospitalization duration (RR, 1.30; 95% CI, 1.25 -1.34). 56 Recently, it was reported that treatment with thiopurines and/or biologics was started more often in patients with proximal small bowel lesions detected by SBCE [13/33 (39%) vs 1/17 (6%), p = 0.011, relative risk (RR) 6.5], particularly when severe (6%, 36% and 45% of patients with non-significant, mild and moderate-to-severe inflammation, respectively).…”